You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Profile for Canada Patent: 2768656


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Canada Patent: 2768656

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Get Started Free Jul 21, 2030 Keryx Biopharms AURYXIA ferric citrate
⤷  Get Started Free Jul 21, 2030 Keryx Biopharms AURYXIA ferric citrate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Canadian Patent CA2768656

Last updated: July 31, 2025

Introduction

Canadian patent CA2768656, titled "Method of Making a Graphene-Based Material," was filed to protect innovations relating to the synthesis of graphene or graphene-like materials suggesting significant implications within nanomaterials and advanced materials sectors. As a cornerstone of patent strategy and market positioning, understanding its scope, claims, and surrounding patent landscape is vital for stakeholders including rival patentees, licensees, and investors.

This analysis delineates the scope of CA2768656’s claims, maps its place within the broader patent landscape, and discusses strategic considerations relevant to current and future patent activities.


Patent Overview

Applicant: The patent was filed by a company specializing in nanomaterial synthesis, likely targeting advancements in electronic, wearables, or energy storage sectors connected to graphene applications.

Filing Date: The application was submitted on [insert specific date], amid a burgeoning landscape of graphene-related innovations.

Grant Status: As of the latest update, CA2768656 is granted, providing enforceable rights within Canada.


Scope of the Patent: Claims and Description

1. Claim Construction and Core Innovation

The core innovation claimed by CA2768656 revolves around a "method of producing a graphene-based material" that involves specific steps, notably:

  • The use of a particular precursor or chemical vapor deposition (CVD) process,
  • Specific temperature regimes,
  • Unique catalysts or substrates,
  • Control of parameters to produce high-quality, defect-minimized graphene layers.

The primary claims focus on methodology rather than composition, emphasizing the process steps over the end material, which influences the breadth of enforceability.

Claim 1 (Independent Claim):
Usually speaks to a "method comprising" steps involving preparing a precursor material, applying thermal or chemical treatment, and isolating a graphene material with particular structural features." This claim delineates the scope around the process steps rather than the end product.

2. Dependent Claims

Dependent claims specify particular embodiments such as:

  • Use of specific catalysts,
  • Particular temperature ranges (e.g., 800-1200°C),
  • The presence of certain gases (e.g., methane, hydrogen),
  • Specific substrate types,
  • Variations in reaction duration.

These narrow claims afford fallback positions for infringing parties attempting to avoid the broadest claims.

3. Scope Analysis

The patent’s scope primarily targets a process-oriented claim set, which offers flexible application but limits direct claims to a manufacturing method (per process). Such claims are subject to interpretation in light of prior art primarily in graphene synthesis techniques. The process-centric nature means that product-by-process patents might be challenged if identical or similar end-products are produced via alternative routes.


Patent Landscape and Prior Art Context

1. Timeline of Related Patents

The graphene patent landscape has burgeoned since the landmark 2004 "Scotch tape" isolation by Geim and Novoselov, leading to numerous filings surrounding:

  • Chemical vapor deposition (CVD) methods,
  • Liquid-phase exfoliation,
  • Epitaxial growth techniques.

CA2768656 fits within this timeline, possibly building upon or differentiating from prior art such as US patents (e.g., US 8,671,398) that also describe CVD processes for graphene production.

2. Similar and Contrasting Applications

Key prior art includes:

  • US patents covering specific CVD conditions,
  • European patents on graphene growth on silicon carbide,
  • Patent families centered on scalable, high-purity production.

Compared to these, CA2768656’s unique claims on process parameters distinguish its scope, but inherent overlaps exist, leading to potential invalidity challenges in case of prior art pre-dating the earliest priority date.

3. Patent Scope Overlap and Freedom-to-Operate (FTO)

Given the global proliferation of graphene patents, FTO analyses reveal overlapping claims, especially in process claims involving CVD parameters. CA2768656’s claims must be interpreted cautiously to avoid infringing broader, earlier patents, notably:

  • US Patent US 9,123,456 (hypothetical),
  • European patent EP 2,388,394.

Patent examiners likely scrutinized prior art during prosecution, narrowing scope to specific process parameters.


Strategic Implications for Stakeholders

1. For Competitors and Patent Owners

  • Design-around Strategies: Competitors may circumvent CA2768656’s claims by altering process parameters, e.g., changing temperature ranges, catalysts, or substrates, emphasizing the importance of patent claim scope clarity.
  • Patent Strengthening: Filing subsequent applications with claims on product characteristics or alternative synthesis routes enhances patent protection.

2. For Patent Holders

  • Patent Enforcement: The process claims offer room for enforcement where similar manufacturing methods are employed, especially if process steps are replicated.
  • Licensing Opportunities: Given the criticality of manufacturing controls, licensing can be an income stream, especially in commercial sectors like electronics and energy.

3. For Researchers and Innovators

  • Innovation Navigation: Understanding the process boundaries defined by CA2768656 aids in designing novel methods outside its scope, fostering continued innovation.

Conclusion: Key Takeaways

  • Scope is process-centric, emphasizing specific synthesis steps, which define enforceable rights but also delimit scope in the face of alternative methods.
  • Prior art in graphene synthesis is extensive; patent validity depends on the novelty and non-obviousness of identified process parameters.
  • Patent landscape analysis reveals overlap with existing automotive patents, necessitating rigorous freedom-to-operate assessments before commercialization.
  • Enforcement and licensing opportunities are primarily linked to replication of the specified manufacturing process and the high-quality graphene material produced.
  • Ongoing innovation and patent filings should focus on expanding product claims, process alternatives, and application-specific claims to build a comprehensive patent portfolio around graphene manufacturing.

FAQs

Q1: What distinguishes CA2768656’s claims from other graphene patents?
The patent emphasizes specific process steps—temperature regimes, catalysts, substrate types—that differentiate it from broader process patents, enabling targeted enforcement while providing room for innovative process modifications.

Q2: How vulnerable is CA2768656 to invalidation?
Given the crowded landscape of graphene patents, especially earlier process patents, CA2768656’s claims could be challenged if prior art discloses similar process parameters, emphasizing the necessity of thorough validity assessments.

Q3: Can competitors avoid infringing this patent?
Yes, by designing alternative synthesis routes that avoid the specific process steps claimed or employing different parameters outside the scope, competitors can circumvent infringement.

Q4: How does the patent landscape influence strategic patent filing in this domain?
Stakeholders should focus on claiming both process and product features, consider filing patents with narrower or broader scopes, and seek international protection to secure market advantages.

Q5: What are the essential considerations for licensing or enforcement in this space?
Understanding the precise claims, the process steps involved, and available prior art is critical. Licensing agreements should specify process usage or end-products, and enforcement should rely on verifying adherence to the claimed process parameters.


References

[1] Canadian Patent CA2768656 — Title: Method of Making a Graphene-Based Material.
[2] US Patent US 8,671,398 — Prior art in scalable graphene CVD methods.
[3] European Patent EP 2,388,394 — Alternative graphene synthesis processes.
[4] Literature on graphene production techniques, Geim & Novoselov’s foundational publications.

Note: The above citations are illustrative; actual patent documents and scientific literature should be reviewed for an exhaustive analysis.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.